BRAF and lentigo maligna melanoma: Genetic changes in neurofibromin 1 (NF1), B-Raf proto-oncogene (BRAF)V600K, non-V600E (glutamic acid substitution) mutations, neuroblastoma RAS viral oncogene homolog (NRAS), and, to a lesser extent, KIT proto-oncogene receptor tyrosine kinase (KIT) are among the varying mutations in lentigo maligna melanoma (LMM) compared with superficial spreading melanoma (SSM) [39].